Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Abstract Text:

Allan Hildesheim,Lauri Markowitz,Mauricio Hernandez Avila,Silvia Franceschi,

Human papillomavirus virus-like particle (HPV VLP) HPV vaccines currently evaluated for licensing are likely to be available soon. Licensure will be based on evidence that the vaccine is well tolerated and provides near complete type-specific protection against HPV infections and their resulting lesions in the first few years after vaccination. Several important questions will remain to be answered after licensure to guide vaccine implementation and to permit the rational evaluation of vaccination in cancer prevention programs. These include the long-term safety and efficacy of vaccination, the optimal ages for vaccination, efficacy against HPV types not included in the vaccine and against existing infections, and efficacy in males. Modulators of vaccine efficacy (e.g., HIV infection) and immune mechanisms of long-term protection also remain to be defined. The real-world effectiveness of vaccination programs will need to be assessed. Issues related to the implementation of a vaccine that targets pre-adolescents and early adolescents and to the acceptability of a cancer vaccine targeted against a sexually transmitted infection will need to be understood before vaccination programs can be successful. It is hoped that continued improvements to the current HPV vaccines will lead to the introduction in future years of second generation vaccines that simplify delivery and/or expand its coverage. Finally, the natural history of HPV types not covered in the candidate vaccines will need to be carefully studied following vaccination. Public health authorities in various countries will play a pivotal role in determining if these questions are answered in a timely manner.

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Publishing Authors By Initials

A Hildesheim,L Markowitz,MH Avila,S Franceschi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Vaccine

VOLUME: 24 Suppl 3

Page Numbers: S227-32

Journal Abbreviation:

ISSN: 0264-410X

DAY: 19

MONTH: 06

YEAR: 2006

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8406899

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.

AFFILIATION: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Room 7062, Rockville, MD, United States Bethesda, MD, United States.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Vaccine

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines Related Publications

• A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (a/g)-308 polymorphism.
• A novel mitochondrial DNA-like sequence insertion polymorphism in Intron I of the FOXO1A gene.
• Analysis of transcription factor interactions in osteoblasts using competitive chromatin immunoprecipitation.
• Back to the future: the ribosome as an antibiotic target.
• Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells.
• Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.
• Common evolutionary origin of the immune and neuroendocrine systems: from morphological and functional evidence to in silico approaches.
• Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development.
• Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation.
• Different types of cell death in organismal aging and longevity: state of the art and possible systems biology approach.
• Erythrocyte plasma membranes obtained from centenarians show different functional properties.
• Healing Cranial Defects with AdRunx2-transduced Marrow Stromal Cells.
• Human longevity within an evolutionary perspective: The peculiar paradigm of a post-reproductive genetics.
• Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland.
• Human papillomavirus types among women infected with HIV: a meta-analysis.
• Immunoproteasome in Macaca fascicularis: No Age-Dependent Modification of Abundance and Activity in the Brain and Insight into an in silico Structural Model.
• In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation.
• Incidence of primary liver cancer in Italy between 1988 and 2002: An age-period-cohort analysis.
• Inflammaging as a major characteristic of old people: can it be prevented or cured?
• Long-term immune-endocrine effects of bereavement: relationships with anxiety levels and mood.
• Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix.
• New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology.
• Paraoxonase 1: genetics and activities during aging.
• Plasma concentrations of interleukin-1-beta, interleukin-6 and tumor necrosis factor-alpha, and of their soluble receptors and receptor antagonist in anorexia nervosa.
• Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey.
• Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe.
• Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea.
• The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.
• Use of a stringent dimerizer-regulated gene expression system for controlled BMP2 delivery.
• Usefulness of the comprehensive geriatric assessment in older patients with upper gastrointestinal bleeding: a two-year follow-up study.